**MONDAY, AUGUST 17**

**Keynote Address**

James P. Allison, University of Texas MD Anderson Cancer Center, USA

Immune Checkpoint Blockade in Cancer Therapy: New Insights into Therapeutic Mechanisms

**Mechanisms of Action I**

*Ira Mellman*, Genentech, Inc., USA

Mechanistic Basis of Cancer Immunotherapy

*Kelli Connolly*, Yale University, USA

Short Talk: Tumor-Draining Lymph Nodes Contain an Untapped Reservoir of Stem-Like CD8 T Cells

AHyun Choi, 275.00

Short Talk: Loss of EMC Inhibits Tumor Growth through Enhanced Adaptive Immune Response

**Mechanisms of Action II**

Jane Oliaro, Peter MacCallum Cancer Centre, Australia

Identifying New Targets for Cancer Immunotherapy

Vandana Kalia, University of Washington and Seattle Children’s Research Institute, USA

Short Talk: PD-1 Signals Are Critical for Maintenance of CD8 T Cell Memory

Katie Campbell, University of California, Los Angeles, USA

Short Talk: Integrating DNA and RNA Sequencing Analysis to Describe Somatic Alterations and Expression in the HLA Gene Loci

Stephen Mok, MD Anderson Cancer Center, USA

Short Talk: Late Interferon-Gamma Blockade Improves Antitumor Efficacy of Anti-CTLA-4 and Anti-PD-1 Combination Treatment

**Mechanisms of Response I**

Siwen Hu-Lieskovan, Huntsman Cancer Institute, USA

Clinical Testing Strategies against Heterogenous Mechanisms of Immune Resistance

Antoni Ribas, University of California, Los Angeles, USA

Mechanisms of Primary and Acquired Resistance to PD-1 Blockade Therapy

Chang Liu, University of Pittsburgh, USA

Short Talk: Neuronalin-1 is a T Cell Memory Checkpoint Limiting Long-Term Anti-Tumor Immunity

**Mechanisms of Response II**

Padmanee Sharma, University of Texas MD Anderson Cancer Center, USA

From the Clinic to the Lab: Investigating Mechanisms of Response and Resistance to Immune Checkpoint Therapy

*Yuxuan Miao*, Rockefeller University, USA

Short Talk: Adaptive Immune Resistance Emerges From Tumor-Initiating Stem Cells

**Poster Session**

**TUESDAY, AUGUST 18**

**Therapeutic Play I**

Yvonne Y. Chen, University of California, Los Angeles, USA

Engineering Next-Generation CAR-T Cell Therapy for Cancer

*Juan C. Jaen*, Arcus Biosciences, Inc., USA

Clinical Applications of Adenosine Pathway Inhibitors

Coralie Backlund, Massachusetts Institute of Technology, USA

Short Talk: Cell Penetrating Peptides Improve T Cell Response to Neoantigenic Peptide Vaccines

Maija Hollmén, University of Turku, Finland

Short Talk: Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumours

Yingxiao Wang, University of California, San Diego, USA

Short Talk: Engineering Remotely Controllable CAR T Cells for Cancer Immunotherapy

**Therapeutic Play II**

*Evan Scott*, Northwestern University, USA

Engineered Nanobiomaterials for Cancer Immunotherapy

E. John Wherry, University of Pennsylvania, USA

Epigenetic Features of Exhausted Antitumor T Cells

Buvana Ravishankar, Rapt Therapeutics, Inc., USA

Short Talk: Targeting the Stress Response Kinase GCN2 Potentiates Anti-Tumor Immune Response

Anthony K. Park, City of Hope, USA

Short Talk: Effective Combination Immunotherapy using Oncolytic Viruses to Deliver CAR Targets to Solid Tumors

Patrick A. Ott, Dana-Farber Cancer Institute, USA

Short Talk: Personal Neoantigen Vaccines Induce Long-term Immune Responses in Patients with High Risk Melanoma

**Meet-the-Editors Roundtable**

Alessandra Fornarelli, Frontiers, Switzerland

Paloma Portela Torres, SAGE Publications Ltd, UK

Lise Roth, European Molecular Biology Organization, Germany

**Genomics of Cancer I**

*Priti Hegde*, Foundation Medicine, USA

Pan-Cancer Analysis of Allele-Specific HLA-I Loss Suggests Widespread Occurrence across a Diverse Range of Tumor Types

Eliezer M. Van Allen, Dana-Farber Cancer Institute, USA

Tumor Genomics and Selective Response to Cancer Immunotherapy

For the most up-to-date details, visit [https://www.keystonesymposia.org](https://www.keystonesymposia.org).
*Nadine A. Defranoux*, Parker Institute for Cancer Immunotherapy, USA
Short Talk: Strategies to Improve the Sensitivity and Ranking Ability of Neoantigen Prediction Methods: Report on the Results of the Tumor NeOantigen SeLection Alliance (TESLA)

**Gloria Bora Kim**, University of Pennsylvania, USA
Short Talk: Splice Variants as Neoantigens for Cancer Immunotherapy

**Genomics of Cancer II**

**Elaine R. Mardis**, Nationwide Children's Hospital, USA
*Immunogenomics and the TME in Pediatric CNS Cancers*

**Thomas D. Wu**, Genentech, Inc., USA
Short Talk: Peripheral T Cell Expansion Predicts Tumor Infiltration and Clinical Response to Cancer Immunotherapy

**Debattama Sen**, Massachusetts General Hospital, USA
Short Talk: Disrupting Enhancers within the Core Epigenetic Program of Exhaustion Improves CD8+ T Cell Responses and Enhances Tumor Control

**WEDNESDAY, AUGUST 19**

**Single Cell I**

**James R. Heath**, Institute for Systems Biology, USA
*Single Cell Approaches to Analyzing Antitumor Responses*

*Ansuman Satpathy*, Stanford University School of Medicine, USA
*Single-Cell Genomics in Cancer Immunotherapy*

**Christine Carine Mousson**, Genentech, Inc., USA
Short Talk: Local Heterogeneity of Response to CIT: Learning from the STAMP Live Imaging Model

**James C. Lee**, University of California, San Francisco, USA
Short Talk: Liver Metastasis Mediated Control of Systemic Tumor-Specific Immunity and Response to Checkpoint Immunotherapy

**Single Cell II**

*Sohail F. Tavazoie*, Rockefeller University, USA
*Depleting Myeloid-Suppressive Cells for Cancer Immunotherapy*

**Theodore Roth**, University of California, San Francisco, USA
Short Talk: Parallel Engineering of Immune Cell Genomes by Pooled Knockin Targeting

**Amanda Oliver**, Peter MacCallum Cancer Centre, Australia
Short Talk: Tissue-Specific Tumour Microenvironments Influence Responses to Immunotherapy